PP
CRSP icon

Paladin Partners’s CRISPR Therapeutics CRSP Stock Holding History

Paladin Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-150
Closed -$8.18K – 206
2026
Q2 		$8.18K Buy
+150
New +$7.91K 0.01% 138

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $937M AUM 18.56% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
HPBT
Hickory Point Bank & Trust Decatur, Illinois $166M AUM 19.36% 1-Year Est. Return

Paladin Partners's CRSP Position: Q3 2026 in Review

Paladin Partners sold out of CRISPR Therapeutics (CRSP) in Q3 2026, closing a stake of 150 shares — an estimated $8.18K sold.

Paladin Partners first reported a position in CRSP in Q2 2026 and held it in 1 quarter. The position peaked at $8.18K in Q2 2026. 13 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Paladin Partners reported no remaining CRISPR Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Paladin Partners sold 150 CRISPR Therapeutics shares in Q3 2026, an estimated $8.18K.
  • Paladin Partners first reported a position in CRISPR Therapeutics in Q2 2026 and held it in 1 quarter.
  • Paladin Partners's CRISPR Therapeutics position peaked at $8.18K in Q2 2026.
  • 13 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.